Ferinject ® approved in Chinafor the treatment of iron deficiency in adult patients
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide.
“We are thrilled about the marketing authorization of Ferinject®, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia”, said Hervé Gisserot, General Manager of CSL Vifor. “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject® can make a meaningful difference in the treatment of these patients. At the same time, this is another important step in our goal to globalizing and maximizing the performance of our iron franchise as we look forward to bring this treatment to market as soon as possible.”
“Marketing authorization of Ferinject® will strengthen our commitment of bringing innovative medicines for patients in China. We are guided by our corporate philosophy of caring for life and invested to putting essential medicines and technologies in the hands of people who help patients and to finding the best answers to the challenges they face”, said Yang Weiping, President of Fresenius Kabi China.
The approval of Ferinject® may also enable a more effective implementation of PBM in Chinese hospitals, where an estimated 3-4 million patients undergo elective surgery each year. In China, PBM encompasses multiple in-hospital procedures across therapeutic areas. The China National Health Commission (NHC) has announced guidelines for perioperative PBM as a health standard across China, effective as per 1 June 2022.
Marketing authorization in China is based on positive clinical results from the phase-III trial VIT-IRON-2011-004. This open label, randomized multicenter study showed that Ferinject® is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.
CSL Vifor and Fresenius Kabi currently expect to begin to market Ferinject® in the first half of 2023, with National Reimbursement Drug List (NRDL) listing anticipated in January 2024.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate mission of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.
Ferinject®/Injectafer® (ferric carboxymaltose) is an i.v. iron therapy with market authorization in 85 countries by November 2022. More than 19 million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2. Ferinject’s® quality relies on a consistent and firmly-controlled manufacturing process based on decades of experience.
About iron deficiency
Iron Deficiency affects about half of the patients with chronic kidney disease3 and chronic heart failure and is associated with reduced quality of life4, an increased risk of hospitalization5 and cardiovascular death6. Despite the serious consequences and high prevalence, of iron deficiency, the condition remains under-recognized7.
Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide8, yet despite the serious consequences and high prevalence9, it remains an under-recognized condition.
Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five10. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being11. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality12. Common symptoms include fatigue11, 13, 14 pale skin13, brittle nails13, 15, craving non-food items such as dirt, clay and ice16, and an inability to concentrate11, 17. In children, iron deficiency can significantly impair cognitive and motor development18.
About Patient Blood Management (PBM)
PBM is designed to improve surgical and medical patient outcomes by optimally managing and preserving patients’ blood. Proactive identification and treatment of iron deficiency anemia in patients scheduled for elective surgery has been associated with a reduced need for blood transfusion19 , reduced length of hospital stay19, improved patient’s outcomes20, and overall healthcare expenditure reduction21.
1. Ni W, Yuan X, Sun Y, et al. Anaemia and associated factors among older adults in an urban district in China: a large-scale crosssectional study. BMJ Open 2022;12:e056100. doi:10.1136/ bmjopen-2021-056100.
2. Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.
3. Wong MMY et al. Clin Kid J 2019:1–12; Rocha BML, et al. J Am Coll Cardiol. 2018;71(7):782–793.
4. Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
5. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
6. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030; Klip IT, et al. Am Heart J. 2013;165:575–82.e3.
7. Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
8. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
9. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.
10. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).
11. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
12. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.
13. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
14. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.
15. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.
16. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
17. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.
18. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.
19. Froessler B. et al., Ann Surg 2016
20. Kotzé A. et al., British Journal of Anaesthesia 2012
21. Basora M. et al., Blood Transfus 2018
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
CSL Vifor Media Contact
Mobile: +41 79 957 96 73
CSL Investor Contact
Associate Director, Investor Relations
Mobile +61 402 231 696
Fresenius Kabi contacts:
China Corporate Communications
+86 010 – 59096999
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WPU to Broaden Research and Development Cooperation With Vitol8.2.2023 08:01:00 CET | Press release
WPU – Waste Plastic Upcycling A/S has welcomed an initiative of Vitol to engage in negotiations of a deeper vertical research and development of the WPU proprietary technology. The aim of this research and development will be to further broaden the product palette offered by WPU and enrich the subsequent treatment by Vitol creating more valuable products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005907/en/ Niels Stielund (WPU) and Tom Baker (Vitol) (Photo: Business Wire) The Research and Development cooperation may include construction of an upcycling facility based on WPU proprietary technology but financed by Vitol. WPU welcomes this initiative and looks forward to the negotiations and will update on significant developments. Tom Baker, Global Head of Naphtha trading at Vitol comments:“Meeting the timeline for construction of the Fårevejle facility is a notable achievement. Vitol believes that the WPU proprieta
Benchmark International and Redox AS Announce New Dealer and Distributor Agreement for Energy Efficient VPSA Oxygen Concentrators7.2.2023 21:20:00 CET | Press release
Benchmark International, a leading manufacturer of the most energy efficient VPSA Oxygen Concentrators, and Redox AS, a leading aquaculture supply company, are pleased to announce a new dealer and distributor agreement within the Norwegian market. This partnership will bring the latest technology in oxygenation systems to the Norwegian aquaculture market, providing farmers with the tools they need to improve efficiency and decrease costs while maintaining the highest standards of fish welfare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207006076/en/ Industry leading, energy efficient VPSA oxygen concentrators from Oxygen Solutions and Benchmark International - a Canadian manufacturer represented by Redox in Norway. (Photo: Business Wire) Under the terms of the agreement, Redox will be the exclusive dealer and distributor of Benchmark International's VPSA Oxygen Concentrators in Norway. These state-of-the-art systems u
Lineage Logistics Announces Lineage Fresh, Expands Fresh Produce Offering In Europe7.2.2023 18:51:00 CET | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide, announced Lineage Fresh, a new strategic service in Europe, launched last November in the US, which provides fresh storage solutions for major importers, grocers, and producers of fresh fruit and produce, as part of its participation in the Fruit Logistica trade show in Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207006000/en/ Fresh blueberries are packed at a Lineage facility. (Photo: Business Wire) Lineage Fresh will allow products with a short shelf-life to face fewer obstacles, less risk, and less spoilage with Lineage’s cold storage technology and leading logistics network. Leveraging the Company’s expertise as a global temperature-controlled storage provider, Lineage Fresh is designed to cater to businesses in which food safety is critical and speed to
Carbios appoints four new Board members to strengthen international expertise in brand development, business growth and scientific research7.2.2023 18:17:00 CET | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005964/en/ Clockwise from left: Mateus SCHREINER GARCEZ LOPES, Sandrine CONSEILLER, Prof. Karine AUCLAIR & Amandine DE SOUZA Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, announces the appointment of four new members to its Board of Directors. Prof. Karine AUCLAIR, professor of Chemistry at McGill University, Sandrine CONSEILLER, former CEO of Aigle, Amandine DE SOUZA, General Manager of LE BHV MARAIS, Eataly and Home, DIY and Leisure Purchasing at Galeries Lafayette Group, and Mateus SCHREINER GARCEZ LOPES, Global Director for Energy Transition and Investments at Raizen, have all been appointed members of Carbios’ Board of Directors. Three of the new members have strong, proven expertise in various industries covering fashion, r
Shufti Pro Launches Risk Assessment & eIDV Solutions to Enable More Reliable Customer Verification7.2.2023 17:58:00 CET | Press release
Pioneer of first-ever on-premises IDV solutions, Shufti Pro, has announced the launch of its risk assessment and eIDV services to help global businesses fight identity fraud and financial crimes, and meet the ever-evolving KYC/AML regulatory landscape. Risk Assessment Solution - is the purposely built tool to help businesses identify risks associated with their globally diverse client base. Shufti Pro’s custom-built risk-scoring solution adapts to the interests of organisations whilst addressing every possible risk factor to safeguard businesses from financial crimes, reputational damages, and regulatory sanctions. It ensures enterprises make informed decisions by evaluating customer risk factors through custom questionnaires and fraud prevention data points, further examined by the Shufti Pro’s risk intelligence profiling engines (a database of over 10B ID elements). eIDV Service - eIDVis the process of verifying customers through a government-issued unique identifier number. It works